Targeting gene fusions in oncology: Proven approach, promising future
Gene fusions may not be as well known as other genomic alterations, but we believe they are a proven class of biomarkers with incredible potential still to be unlocked.
Read More
Gene fusions may not be as well known as other genomic alterations, but we believe they are a proven class of biomarkers with incredible potential still to be unlocked.
Read MoreHosted by: Solebury Trout, White & Case, and Oppenheimer
Read MoreAn inside look on the launch of Elevation Oncology during 2020 and the COVID-19 pandemic, and the lessons we’ll carry forward into 2021!
Read MoreWhat are PDX models, and why are they important to precision medicine? We break down the term in this infographic!
Read MoreWith the advent of the ‘precision oncology’ movement, the success of biomarker-driven targeted therapies has fundamentally changed our approach to drug development and treatment selection.
Read MoreThe anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
Read MorePresentation of data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Read MoreTrial in Progress: the CRESTONE study with Dr. David Spiegel
Read MoreTrial in Progress: the CRESTONE study with Dr. Johanna Bendell
Read More$32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners
Read More